VIR earnings

Vir Biotechnology, Inc. (NASDAQ:VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, May 6 to provide a corporate update and discuss its financial results for the first quarter ended March 31, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-mas

– Announces global strategic collaboration with Astellas to advance PSMA-targeted PRO-XTEN® dual-masked T-cell engager (TCE) VIR-5500 for the treatment of prostate cancer – Reports updated VIR-5500 Phase 1 dose-escalation data supporting a favorable safety profile and promising anti-tumor activity – Strong financial position with $781.6 million in cash and investments as of December 31, 2025 – Conference call scheduled for February 23, 2026, at 5:30 p.m. ET / 2:30 p.m. PT Vir Biotechnology, Inc. (NASDAQ:VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2025. "This is a seminal moment for Vir Biotechnology

– Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a favorable safety profile and was well tolerated with no dose-limiting toxicities observed to date – Dose-dependent anti-tumor activity was observed, with 82% PSA50 and 53% PSA90 declines and RECIST-evaluable objective responses (45% ORR in 5/11 patients) in ≥3,000 µg/kg Q3W dosing cohorts – Vir Biotechnology to host conference call today at 5:30 p.m. ET / 2:30 p.m. PT – Data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium on February 26 (Oral Abstract #17) Vir Biotechnology, Inc. (NASDAQ:VIR) today announced new data from the ongoing Phase 1 clinical tri

- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues -- Astellas to lead commercialization of VIR-5500 in the U.S. with Vir Biotechnology retaining option to co-promote, and Astellas will obtain exclusive rights to commercialize VIR-5500 ex-U.S. -- Vir Biotechnology will receive $335M in upfront and near-term milestone payments, will split U.S. profit/loss equally with Astellas (50/50), and is eligible to receive up to an additional $1.37B in development, regulatory and sales milestones, along with tiered, double-digit royalties on ex-U.S. net sales - - Vir Biotechnology to host conference call today at 2:30 p.m. PT / 5:30 p.

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that it will host a conference call at 5:30 p.m. ET / 2:30 p.m. PT on Monday, February 23 to provide a corporate update and discuss its financial results for the fourth quarter and full year ended December 31, 2025. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multipl

- ECLIPSE 1 enrollment completed approximately two months ahead of schedule; ECLIPSE 2 and ECLIPSE 3 progressing with strong enrollment momentum, with topline data for all three studies expected in the first quarter of 2027 - Comprehensive data update for VIR-5500, a PSMA-targeting PRO-XTEN® dual-masked T-cell engager, planned for the first quarter of 2026 - First patient dosed in Phase 1 study of VIR-5500 in combination with androgen receptor pathway inhibitors (ARPIs) in first-line metastatic castration-resistant prostate cancer - Strong financial position and runway into mid-2027 with $810.7 million in cash and investments as of September 30, 2025 - Conference call scheduled for Nove

Vir Biotechnology, Inc. (NASDAQ:VIR), today announced that the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2025, on November 5, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on November 5, 2025. The corporate update and financial results will be provided via a press release shortly after market close and will be accessible on the News page in the Investors section of the Vir Biotechnology website. The webcast may be accessed on the Events & Presentations page of the Vir Biotechnology website. Participants must register in advance to receive a unique webcast access link. An archived replay wil

– ECLIPSE registrational program in chronic hepatitis delta fully underway – First patient dosed in Phase 1 study of VIR-5525, an EGFR-targeting PRO-XTEN™ dual-masked T-cell engager; advancing oncology clinical pipeline with three ongoing Phase 1 studies – Strong financial position and runway into mid-2027 with approximately $892.1 million in cash and investments as of June 30, 2025 – Conference call scheduled for August 6, 2025 at 1:30 p.m. PT / 4:30 p.m. ET Vir Biotechnology, Inc. (NASDAQ:VIR), today provided a corporate update and reported financial results for the second quarter ended June 30, 2025. "We achieved several important milestones across our pipeline, reflecting our

Vir Biotechnology, Inc. (NASDAQ:VIR), today announced that the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2025, on August 6, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on August 6, 2025. The corporate update and financial results will be provided via a press release shortly after market close and will be accessible on the News page in the Investors section of the Vir Biotechnology website. Participants may access the conference call via webcast on the Events & Presentations page of the Vir Biotechnology website or via phone by dialing the U.S. toll free number +1 (888) 800-8770 or internation

- Initiated Phase 3 registrational ECLIPSE program in chronic hepatitis delta with first patient enrolled in Q1 2025; Program received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME and Orphan Drug designations - Dose escalation continues for PRO-XTEN™ dual-masked T-cell engagers VIR-5818 (HER2) and VIR-5500 (PSMA) - On track to initiate a Phase 1 study of VIR-5525, the PRO-XTEN™ dual-masked EGFR-targeting T-cell engager, in the second quarter of 2025 - 24-week post-treatment data from Phase 2 MARCH study in chronic hepatitis B to be presented at EASL on May 9; Further development requires partner - Strong financial position with approximately $1.0 billion in cash and i

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2025, on May 7, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on May 7, 2025. The corporate update and financial results will be provided via a press release shortly after market close and will be accessible on the News page in the Investors section of the Vir Biotechnology website. Participants may access the conference call via webcast on the Events & Presentations page of the Vir Biotechnology website or via phone by dialing the U.S. toll free number +1 (888) 800-8770 or international numbe

Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure Data from Multiple Ongoing Late-Stage Studies Reinforce Brii Bio's HBV Functional Cure Strategy of Optimized Combination Regimens to Target Patient Populations 4 Abstracts Including 2 Oral Presentations with Data from the Ongoing Phase 2 ENSURE Study at the Upcoming APASL (March 26-30) Strong Cash Reserves of US$335.7 Million to Propel Operations into 2028 Actively Seeking Partnership Opportunities for Non-HBV Programs Conference Call (English Session) Scheduled for March 31 at 8:30 PM HKT / 8:30 AM ET DURHAM, N.C. and BEIJING, China,

- Phase 3 ECLIPSE registrational clinical program in chronic hepatitis delta on track to begin in the first half of 2025 - Tobevibart and elebsiran in chronic hepatitis delta received U.S. FDA Breakthrough and Fast Track designations and EMA PRIME and Orphan Drug designations - Compelling early clinical response signals and promising safety profiles for dual-masked T-cell engagers VIR-5818 and VIR-5500 in heavily pretreated patients with solid tumors, with potential for expanded therapeutic index - Company plans to initiate a Phase 1 study of VIR-5525, its dual-masked EGFR-targeting T-cell engager, in the first half of 2025 - Focused prioritization and disciplined capital deployment

Vir Biotechnology, Inc. (NASDAQ:VIR), today announced that the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2024, on February 26, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on February 26, 2025. The corporate update and financial results will be provided via a press release after market close and will be accessible on the News page in the Investors section of the Vir Biotechnology website. Participants may access the conference call via webcast on the Events & Presentations page of the Vir Biotechnology website or via phone by dialing the U.S. toll free number +1 (888) 800-877

– Compelling early clinical response signals for VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors ○ VIR-5818: In patients receiving doses ≥400 µg/kg, tumor shrinkage observed in 50% (10/20) of participants with various HER2-expressing cancers; confirmed partial responses in 33% (2/6) of participants with HER2-positive CRC ○ VIR-5500: PSA declines in 100% (12/12) and PSA50 response confirmed in 58% (7/12) of mCRPC patients with first step dose ≥120 µg/kg – Promising safety profile with MTD not yet reached for VIR-5818 or VIR-5500 and no dose-limiting cytokine release syndrome (CRS) observed; no CRS greater than grade 2 reported – Initial clinical data de

– Monthly tobevibart and elebsiran combination achieves rapid 100% virologic suppression at Week 24, sustained through Week 60 – – Undetectable HDV RNA in 41% of participants at Week 24, increasing to 64% by Week 36 and up to 80% by Week 60 across cohorts – – Combination well-tolerated: no treatment-related severe AEs, treatment-related discontinuations or ALT flares – – Following a recent FDA meeting, Phase 3 ECLIPSE registrational program to begin in the first half of 2025 – – New data presented at AASLD The Liver Meeting. Investor conference call November 19, 2024, at 5.15 a.m. PT / 8.15 a.m. ET – Vir Biotechnology, Inc. (NASDAQ:VIR) today announced positive results from the SO

– Orphan designation in E.U. supports development of treatments for life-threatening or chronically debilitating conditions with significant unmet medical need – – Phase 2 SOLSTICE 24-week primary endpoint data for tobevibart and elebsiran in chronic hepatitis delta to be presented today at AASLD The Liver Meeting – – Positive opinion on E.U. orphan drug designation follows U.S. FDA fast track designation, highlighting growing recognition of the potential of tobevibart and elebsiran in chronic hepatitis delta – Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has issued a positive opinion on t

– 39% of participants with low baseline Hepatitis B surface antigen (HBsAg) achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated interferon alfa – – No new safety concerns were identified, and treatment-emergent adverse events were generally mild to moderate – – Late-breaking oral presentation of MARCH Part B study results at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® – – Key functional cure data from 24-week follow-up expected in Q2 2025 – Vir Biotechnology, Inc. (NASDAQ:VIR) today announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of tobevibart

– Successful closing of exclusive worldwide licensing agreement with Sanofi for three potential best-in-class clinical-stage dual-masked T-cell engagers with initial clinical data anticipated in Q1 2025 – – Key Phase 2 SOLSTICE data in chronic hepatitis delta to be presented at AASLD 2024 – – The Company will host a Hepatitis Investor Event following AASLD on November 19, 2024 – – Jason O'Byrne appointed as Chief Financial Officer – – Conference call scheduled for October 31, 2024 at 1:30 p.m. PT / 4:30 p.m. ET – Vir Biotechnology, Inc. (NASDAQ:VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024. "This quarter was transf

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2024, on October 31, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on October 31, 2024. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. Participants may access the conference call via webcast on the Events & Presentations page of Vir's website at https://investors.vir.bio/events-presentations or listen in by dialing the U.

– Positive preliminary Phase 2 chronic hepatitis delta study data presented at EASL™ Congress 2024, FDA IND clearance with Fast Track Designation received underscoring the potential of combination therapy – – Exclusive license agreement with Sanofi bolsters clinical pipeline – – Strategic workforce restructuring and phasing out of influenza, COVID-19, and the Company's T cell-based viral vector platform programs – – $1.43 billion in cash, cash equivalents and investments as of June 30, 2024 – – The Company lowers full-year 2024 operating expense guidance – – Conference call scheduled for August 1, 2024 at 1:30 p.m. PT / 4:30 p.m. ET – Vir Biotechnology, Inc. (NASDAQ:VIR) today p

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024. Financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. Participants may access the conference call via webcast on the Events & Presentations page of Vir's website at https://investors.vir.bio/events-presentations or listen in by dialing the U.S. toll free number (800) 715-9871 or international +1 (646) 3

– Preliminary Phase 2 SOLSTICE trial data reinforce the potential of both regimens to be transformative treatments in an area of high unmet medical need – – Conference call scheduled for June 5, 2024, at 6:00 a.m. ET / 12:00 p.m. CEST – Vir Biotechnology, Inc. (NASDAQ:VIR) today announced new preliminary data from its Phase 2 SOLSTICE hepatitis delta clinical trial evaluating tobevibart, an investigational monoclonal antibody, and elebsiran, an investigational small interfering ribonucleic acid, for the treatment of people living with chronic hepatitis delta. Preliminary data from the Phase 2 trial show treatment with tobevibart alone or in combination with elebsiran was generally well

– Company to present important new data from the Phase 2 SOLSTICE chronic hepatitis delta trial – – Conference call scheduled for June 5, 2024, at 6:00 a.m. ET / 12:00 p.m. CEST – Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that three abstracts highlighting new data from the Company's chronic hepatitis delta and chronic hepatitis B programs have been accepted for presentation at the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2024, taking place in Milan, Italy from June 5-8. This includes an oral presentation on June 8, which was originally accepted as a late-breaker poster, that will highlight the Company's latest Phase 2 SOLSTICE tria

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the EASL Congress has changed the Company's Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation. The SOLSTICE data will be presented on June 8 during the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2024, taking place in Milan, Italy, June 5-8. The Company plans to host an investor conference call to discuss the new SOLSTICE data on June 5. The update will include data on participants that have reached 12 and 24 weeks of chronic suppressive treatment. The Company will also share 48-week treatment data on the efficacy and safety of tobevibart and elebsira

– Late-breaker SOLSTICE data abstract accepted for poster presentation at the European Association for the Study of the Liver (EASL) Congress 2024 – – Two additional hepatitis program data readouts on track for the fourth quarter 2024 – – $1.51 billion in cash, cash equivalents and investments as of March 31, 2024 – – Conference call scheduled for May 2, 2024 at 1:30 p.m. PT / 4:30 p.m. ET – Vir Biotechnology, Inc. (NASDAQ:VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024. "We are excited to share important data from our Phase 2 chronic hepatitis delta SOLSTICE trial at the upcoming EASL congress. This milestone brings

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. Participants may access the conference call via webcast on the Events & Presentations page of Vir's website at https://investors.vir.bio/events-presentations or listen in by dialing the U.S. toll free

Transitioning HBV cure programs into multiple late-stage combination studies with interim results throughout 2024 and 2025 informing Company's registrational strategy Integrating R&D, manufacturing and commercial upsides by acquiring full intellectual property rights of BRII-179 and expanding its manufacturing footprint Prioritizing company resources with a robust cash balance of US$376 million supporting operations until 2027 Company to host a conference call (English session) on March 25 at 8:30 AM ET / 8:30 PM HKT DURHAM, N.C. and BEIJING, March 22, 2024 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapie

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter ended December 31, 2023, on February 22, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on February 22, 2024. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. Participants may access the conference call via webcast on the Events & Presentations page of Vir's website at https://investors.vir.bio/events-presentations. A recorded version of the

– Initial SOLSTICE data suggests the potential of VIR-3434 + VIR-2218 to address the unmet need for a highly efficacious hepatitis delta therapy – – New MARCH Part B data demonstrate that VIR-3434 may play an important role in achieving a functional cure for chronic hepatitis B – – Conference call scheduled for 1:45 p.m. PT / 4:45 p.m. ET, November 13, 2023 – Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will be presenting new data from its ongoing Phase 2 SOLSTICE and MARCH trials evaluating the potential clinical impact that VIR-3434, an investigational monoclonal antibody (mAb), and VIR-2218, an investigational small interfering ribonucleic acid (siRNA), could have for ch

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) patients at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023. These include one late-breaking poster presentation and one late-breaking oral presentation. Late-Breaking Presentations Title: VIR-2218 and VIR-3434 With or Without Pegylated Interferon Alfa-2A for the Treatment of Chronic HBV Infection: End of Treatment (EOT) Results After 24 Weeks o

– Company to present new data at AASLD from Phase 2 chronic hepatitis B and chronic hepatitis delta clinical trials – – Company expanding strategic focus to autoimmune diseases and immuno-oncology – – Jennifer Towne, Ph.D., appointed as Executive Vice President and Chief Scientific Officer, effective November 6, 2023 – – Secured new BARDA funding for the development of RNA-delivered monoclonal antibodies – – $1.7 billion in cash, cash equivalents and investments as of September 30, 2023 – – Conference call scheduled for 1:30 p.m. PT / 4:30 p.m. ET, November 2, 2023 – Vir Biotechnology, Inc. (NASDAQ:VIR) today provided a corporate update and reported financial results for the thi

SAN FRANCISCO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2023, on November 2, 2023. The Company will host a conference call at 4:30 p.m. Eastern Time on November 2, 2023. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. Participants may access the conference call via webcast on the Events & Presentations page of Vir's website at https://investors.vir.bio/events-presentations. A re

First patient dosed in a PEG-IFN-α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HBV functional cure First of several studies to investigate the potential of BRII-179 in enriching patients with strong intrinsic anti-HBsAg responses for curative treatments to start before the end of 2023 Regulatory submissions and preparation for launches of PreHevbri® in APAC countries and regions are underway Near-term revenue opportunities with PreHevbri® and strong balance sheet supporting operations through 2026 Company to host earnings call on August 22 at 8:00 PM ET / August 23 at 8:00 AM HKT and an HBV R&D Day on August 24 from 1:00-2:30 PM HKT DURHAM, N.C. and BEIJING, Aug. 22, 2023 /

– Phase 2 data readouts from ongoing chronic hepatitis B and chronic hepatitis delta programs on track for Q4 2023 – – Increased focus on proprietary antibody platform and discontinuation of Vir's innate immunity small molecule platform – – First participant to be dosed in Phase 1 trial of next-generation HIV vaccine, VIR-1388, anticipated in Q3 – – $1.9 billion in cash, cash equivalents and investments as of June 30, 2023 – – Conference call scheduled for 1:30 p.m. PT / 4:30 p.m. ET, Aug. 3, 2023 – SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today provided a corporate update and reported financial results for the second quarter ended June 30,

SAN FRANCISCO, July 26, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2023 on August 3, 2023. The Company will host a conference call at 4:30 p.m. Eastern Time on August 3, 2023. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. Participants may access the conference call via webcast on the Events & Presentations page of Vir's website at https://investors.vir.bio/events-presentations. A recorded ve

SAN FRANCISCO, July 20, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy endpoints. In participants who received the highest dose of VIR-2482 (1,200 mg), a non-statistically significant reduction of approximately 16% in influenza A protocol-defined illness was observed. Participants who received the highest dose showed an approximately 57% reduction in symptomatic influenza A illness, when defined according to CDC influenza-like-illness criteria, which was one of two seco

Company maintains priority focus on clinical programs to develop a novel functional cure for hepatitis B viral (HBV) infection and a potential first-of-its-kind treatment for postpartum depression (PPD) and major depressive disorders (MDD) Multiple Phase 2a proof-of-concept (POC) clinical data readouts and Phase 2b clinical trial initiations expected in 2023 Operations well-funded through 2025 Company to host conference call today at 8:00 PM HKT / 8:00 AM ET DURHAM, N.C. and BEIJING, March 24, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across disease

SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2022, on Thursday, February 23, 2023. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. About Vir BiotechnologyVir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembl

SAN FRANCISCO, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2022, on Thursday, November 3, 2022. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. About Vir BiotechnologyVir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology

SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2022, on Thursday, August 4, 2022. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. About Vir BiotechnologyVir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platfo

SAN FRANCISCO, April 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2022, on Thursday, May 5, 2022. The update will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. About Vir BiotechnologyVir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate

SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2021, on Thursday, February 24, 2022. The update will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. About Vir BiotechnologyVir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that ar

SAN FRANCISCO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) announced that Management will host a conference call at 8:30 am ET, Tuesday, December 7, 2021, to discuss new data that demonstrates sotrovimab retains activity against the full combination of mutations in the spike protein of the Omicron SARS-CoV-2 variant. To access the call via telephone, please dial (833) 727-9519 (North America) or (830) 213-7696 (International), conference ID: 9894016. A live webcast of the call can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days. About Vir BiotechnologyVir Biotechnology i

SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2021 on Thursday, November 4, 2021. The update will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. About Vir BiotechnologyVir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed t

SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2021 on Thursday, August 5, 2021. The update will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. About Vir BiotechnologyVir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate